Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. In the business of biotechnology, a rising tide can ...

The stock dropped, despite fairly positive data. Investors are worried about long-term efficacy. There's also concern about side effects, although that may be tied to the disease rather than the drug.

Compass Pathways has raised $80 million to prepare its psilocybin therapy for phase 3 development. The London-based biotech is advancing the drug, the active ingredient in magic mushrooms, for use in ...

PRINCETON, N.J.--(BUSINESS WIRE)--Certara ®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that the entire ...

Welcome to State of Mind, a new section from Slate and Arizona State University dedicated to exploring mental health. Follow us on Twitter. Psychedelic drugs are still classified as Schedule 1 drugs, ...

Compass Pathways Plc., a U.K. startup backed by tech billionaire Peter Thiel and lead investor Christian Angermayer, has filed to go public about four years after it was founded to explore the use of ...

Shares of Compass Pathways PLC climbed on Friday after the U.S.-listed healthcare group announced a successful follow-up study of a psychedelic drug used to treat major depression in cancer patients.